Recombinant HEV nanoparticles are perfect vehicles for site-specif delivery of therapeutic and diagnostic agents. Tumor tissue targeting ligand can readily be conjugated to the surface of HEVNP &  with 60 identical protruding arms, the acuracy and precision of finding the tumor site significantly high. Once HEVNP reaches its destination, the cargo is released into the cell and extracellular environment to eradicate the tumor. 

Cancer therapies are trending towards improved targeting and stable circulation methods, such that cancer treatments can attack tumors while minimizing harm to healthy tissues. HEVNPs not only provide a platform that can be modified to target a variety of cancer cells, but also serve as vehicles for delivering cancer drugs. In this way, a tumor-targeted HEVNP can be packaged with drug – or nucleic acid, if a gene therapy approach is used – and deliver it to the tumor site. 

One could envisage adding magnetic nanoparticles to the HEVNP cargo to provide an additional layer of targeting via an externally applied magnetic field. In any case, the consequence of our approach is that cancer therapies would not broadly circulate in healthy tissues; rather, a specific dose would be packaged in the HEVNPs, delivered systemically, and released locally at the tumor site, reducing the potential for side-effects.


HEVNP NanoCarrier Platform
In an interview by MedGadget.com, Dr. Marie Stark and post-doctoral scientist Dr. Prasida Holla explain the conceptual fundamentals of Hepatitis E Virus nanoparticles (HEVNP), an immunogen and drug delivery platform. Utilization of this non-infectious carrier towards mucosal drug delivery, is an innovative approach towards cancer drug delivery, specifically addressed towards the active cancerous tissue, resulting in eradication of chronic and acute infection. The potency and effectiveness of the patented technology of HEVNPs has been carefully tested in previous years by Dr. Holland Cheng’s laboratory based in UC Davis. The Hepatitis E Virus capsid structure evolved for stability in the human body and thus can be used for efficient host cell binding and drug delivery. This revolutionary finding is a major competitor for mucosal drug/immunogen delivery.